Table 1.
Baseline Clinical Characteristics and Cancer Treatment
| Overall (n=141) | |
|---|---|
| Patient demographics | |
| Age (years) | 54.0±11.5 |
| Age >65 | 27 (19.2) |
| BMI (kg/m2) | 21.9±3.3 |
| Underweight (≤18.4) | 22 (15.6) |
| Normal (18.5–24.9) | 90 (63.8) |
| Overweight (25.0–29.9) | 27 (19.2) |
| Obese (≥30.0) | 2 (1.4) |
| CVRF | 14 (9.9) |
| Hypertension | 6 (4.3) |
| Diabetes mellitus | 3 (2.1) |
| Hypercholesterolemia | 10 (7.1) |
| Cardiac disease | 1 (0.7) |
| Breast cancer treatment | |
| Trastuzumab treatment (months) | 11.0 (10.7–13.3) |
| Adjuvant chemotherapy | 74 (52.5) |
| Neoadjuvant chemotherapy | 67 (47.5) |
| Anthracyclines | 133 (94.3) |
| Epirubicin (mg/m2) | 400.0 (266.1–412.6) |
| Cyclophosphamide | 128 (90.8) |
| 5-FU | 128 (90.8) |
| Taxanes | 80 (56.7) |
| Endocrine treatment | 5 (3.6) |
| RT (All) | 75 (53.2) |
| Dose (Gy) | 44.0 (41.0–49.8) |
| Left Breast | 41 (29.1) |
| Dose (Gy) | 44.0 (40.7–49.6) |
| Right Breast | 36 (25.5) |
| Dose (Gy) | 47.0 (40.5–49.8) |
Data given as n (%), mean±SD or median (IQR). Endocrine treatment includes aromatase inhibitors (anastrozole, letrozole), selective estrogen receptor modulator (tamoxifen), and GnRH agonist (goserelin). 5-FU, 5-fluorouracil; BMI, body mass index; CVRF, cardiovascular risk factors; RT, radiotherapy.